Kinnate Zeroes In On BRAF Subpopulation For Exarafenib Development Strategy

BeiGene And Partners Present RAF Dimer Inhibitor Data

 
• By Alaric DeArment
Kinnate presented Phase I data for its pan-RAF inhibitor, exarafenib • Source: Shutterstock

More from Anticancer

More from Therapeutic Category